Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Leporrier

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
La Revue Du Praticien|January 23, 2009
[Chronic lymphocytic leukemia]Michel Leporrier
Presse Medicale (Paris, France : 1983)|March 23, 2010
[Type 1 Gaucher disease and pregnancy]Michel Leporrier
La Revue Du Praticien|April 28, 2004
[Chronic lymphocytic leukemia]Michel Leporrier
The Hematology Journal : the Official Journal of the European Haematology Association|April 14, 2004
Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemiaMichel Leporrier
La Revue Du Praticien|April 1, 2003
[Hemogram: indications and interpretation. Diagnostic orientation]Stéphane Chèze, Michel Leporrier
La Revue Du Praticien|April 17, 2004
[Iron deficiency anaemia]Michel Leporrier, Amélie Seguin
Leukemia Research|June 3, 2006
Infliximab in chronic myelogenous leukemiaHervé Mittre, Christian Marcelli, Michel Leporrier
Case Reports in Medicine|November 19, 2009
Full response of a localized renal tumour after reduced-intensity conditioned hematopoietic stem cell transplantationAnne-Claire Gac, Sylvain Chantepie, Michel Leporrier, et al.
Molecular Pharmaceutics|April 16, 2016
Comparative Analysis between [(18)F]Fludarabine-PET and [(18)F]FDG-PET in a Murine Model of InflammationNarinée Hovhannisyan, Martine Dhilly, Stéphane Guillouet, et al.
EJNMMI Research|May 16, 2015
Evaluation of the specificity of [(18)F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [(18)F]FDG and impact of rituximab therapyNarinée Hovhannisyan, Stéphane Guillouet, Fabien Fillesoye, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
La Revue Du Praticien|January 23, 2009
[Chronic lymphocytic leukemia]Michel Leporrier
Presse Medicale (Paris, France : 1983)|March 23, 2010
[Type 1 Gaucher disease and pregnancy]Michel Leporrier
La Revue Du Praticien|April 28, 2004
[Chronic lymphocytic leukemia]Michel Leporrier
The Hematology Journal : the Official Journal of the European Haematology Association|April 14, 2004
Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemiaMichel Leporrier
La Revue Du Praticien|April 1, 2003
[Hemogram: indications and interpretation. Diagnostic orientation]Stéphane Chèze, Michel Leporrier
La Revue Du Praticien|April 17, 2004
[Iron deficiency anaemia]Michel Leporrier, Amélie Seguin
Leukemia Research|June 3, 2006
Infliximab in chronic myelogenous leukemiaHervé Mittre, Christian Marcelli, Michel Leporrier
Case Reports in Medicine|November 19, 2009
Full response of a localized renal tumour after reduced-intensity conditioned hematopoietic stem cell transplantationAnne-Claire Gac, Sylvain Chantepie, Michel Leporrier, et al.
Molecular Pharmaceutics|April 16, 2016
Comparative Analysis between [(18)F]Fludarabine-PET and [(18)F]FDG-PET in a Murine Model of InflammationNarinée Hovhannisyan, Martine Dhilly, Stéphane Guillouet, et al.
EJNMMI Research|May 16, 2015
Evaluation of the specificity of [(18)F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [(18)F]FDG and impact of rituximab therapyNarinée Hovhannisyan, Stéphane Guillouet, Fabien Fillesoye, et al.
Pageof 3